Federated Hermes Inc. Acquires 500,046 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Federated Hermes Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,883,775 shares of the company’s stock after purchasing an additional 500,046 shares during the quarter. Federated Hermes Inc. owned 0.06% of IDEAYA Biosciences worth $138,185,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Walleye Capital LLC bought a new stake in shares of IDEAYA Biosciences in the third quarter worth $2,265,000. Boone Capital Management LLC lifted its position in shares of IDEAYA Biosciences by 15.0% in the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock worth $15,397,000 after purchasing an additional 74,249 shares in the last quarter. Barclays PLC increased its holdings in IDEAYA Biosciences by 17.8% during the third quarter. Barclays PLC now owns 86,326 shares of the company’s stock worth $2,330,000 after buying an additional 13,049 shares during the last quarter. Eventide Asset Management LLC acquired a new position in IDEAYA Biosciences during the third quarter worth $9,038,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in IDEAYA Biosciences by 405.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,453 shares of the company’s stock worth $265,000 after buying an additional 5,979 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Down 3.6 %

Shares of IDYA stock traded down $1.45 on Thursday, hitting $38.72. The company’s stock had a trading volume of 172,258 shares, compared to its average volume of 848,319. The stock’s 50 day moving average is $44.19 and its 200-day moving average is $36.93. IDEAYA Biosciences, Inc. has a fifty-two week low of $14.33 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.05). The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -2.26 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on IDYA. Royal Bank of Canada boosted their target price on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. BTIG Research began coverage on shares of IDEAYA Biosciences in a report on Friday, March 8th. They set a “buy” rating and a $55.00 target price on the stock. The Goldman Sachs Group boosted their target price on shares of IDEAYA Biosciences from $36.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Citigroup boosted their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, March 21st. Finally, Capital One Financial restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Thursday, February 22nd. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $44.55.

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 23,557 shares of IDEAYA Biosciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the transaction, the chief executive officer now owns 677,887 shares of the company’s stock, valued at approximately $30,870,973.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Yujiro S. Hata sold 23,557 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $45.54, for a total value of $1,072,785.78. Following the completion of the sale, the chief executive officer now owns 677,887 shares in the company, valued at approximately $30,870,973.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Briseno Andres Ruiz sold 2,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $46.02, for a total value of $92,040.00. Following the sale, the insider now directly owns 24,531 shares of the company’s stock, valued at approximately $1,128,916.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,557 shares of company stock worth $1,248,886. Corporate insiders own 5.10% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.